Petri Bono
About
Petri Bono is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, Petri Bono has authored 156 papers receiving a total of 7.5k indexed citations (citations by other indexed papers that have themselves been cited), including 80 papers in Oncology, 73 papers in Pulmonary and Respiratory Medicine and 46 papers in Molecular Biology. Recurrent topics in Petri Bono's work include Renal cell carcinoma treatment (35 papers), Cancer Immunotherapy and Biomarkers (28 papers) and HER2/EGFR in Cancer Research (21 papers). Petri Bono is often cited by papers focused on Renal cell carcinoma treatment (35 papers), Cancer Immunotherapy and Biomarkers (28 papers) and HER2/EGFR in Cancer Research (21 papers). Petri Bono collaborates with scholars based in Finland, United States and United Kingdom. Petri Bono's co-authors include Heikki Joensuu, Sirpa Jalkanen, Vesa Kataja, Kari Alitalo, Marko Salmi, Pipsa Saharinen, Lauri Eklund, Stefan Michiels, Sherene Loi and Debora Fumagalli and has published in prestigious journals such as Journal of Clinical Investigation, The Journal of Experimental Medicine and Journal of Clinical Oncology.
In The Last Decade
Petri Bono
153 papers receiving 7.4k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Petri Bono Finland | 44 | 3.9k | 2.7k | 2.4k | 1.6k | 1.3k | 156 | 7.5k | ||
| E. Gabriela Chiorean United States | 42 | 4.7k 1.2× | 2.1k 0.8× | 1.5k 0.6× | 1.7k 1.1× | 1.7k 1.4× | 209 | 7.1k | ||
| Robert R. McWilliams United States | 46 | 5.9k 1.5× | 2.4k 0.9× | 1.9k 0.8× | 1.9k 1.2× | 645 0.5× | 206 | 8.4k | ||
| Ferry A.L.M. Eskens Netherlands | 43 | 2.9k 0.7× | 2.6k 1.0× | 1.5k 0.6× | 1.2k 0.8× | 461 0.4× | 161 | 6.4k | ||
| Helmut E. Gabbert Germany | 44 | 2.2k 0.6× | 2.8k 1.0× | 1.7k 0.7× | 954 0.6× | 622 0.5× | 126 | 6.2k | ||
| Catherine Delbaldo France | 20 | 6.3k 1.6× | 1.8k 0.7× | 2.7k 1.1× | 2.2k 1.4× | 523 0.4× | 48 | 8.3k | ||
| Joseph P. Eder United States | 47 | 8.2k 2.1× | 3.4k 1.3× | 3.2k 1.3× | 1.6k 1.0× | 2.9k 2.3× | 178 | 12.2k | ||
| Marisa Dolled‐Filhart United States | 34 | 8.1k 2.1× | 2.4k 0.9× | 4.8k 2.0× | 1.8k 1.1× | 1.9k 1.5× | 69 | 11.3k | ||
| Napoleone Ferrara United States | 12 | 5.7k 1.5× | 3.6k 1.3× | 2.4k 1.0× | 1.8k 1.1× | 509 0.4× | 16 | 9.6k | ||
| Maurizio Martini Italy | 44 | 1.9k 0.5× | 2.3k 0.9× | 1.1k 0.4× | 1.3k 0.8× | 614 0.5× | 281 | 6.5k | ||
| Laura D. Wood United States | 46 | 5.2k 1.4× | 3.1k 1.2× | 1.6k 0.7× | 2.9k 1.9× | 513 0.4× | 155 | 8.6k |
Countries citing papers authored by Petri Bono
Since
Specialization
Citations
This map shows the geographic impact of Petri Bono's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Petri Bono with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Petri Bono more than expected).
Fields of papers citing papers by Petri Bono
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Petri Bono. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Petri Bono. The network helps show where Petri Bono may publish in the future.
Co-authorship network of co-authors of Petri Bono
This figure shows the co-authorship network connecting the top 25 collaborators of Petri Bono. A scholar is included among the top collaborators of Petri Bono based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Petri Bono. Petri Bono is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Zeidan, Amer M., Anthony S. Stein, Johanna Rimpiläinen, et al.. (2025). Efficacy, molecular and translational analysis of TP53-mutated HR-MDS with bexmarilimab and azacitidine: Updated results from the bexmab Phase 1/2 study. Blood. 146(Supplement 1). 236–236.
2.
Lillrank, Paul, et al.. (2024). The impact of COVID-19 on private healthcare service utilisation: time series analysis in the capital region of Finland during 2020–2022. BMC Public Health. 24(1). 3100–3100.
3.
Huuhtanen, Jani, Katriina Peltola, Tapio Lönnberg, et al.. (2023). Single-cell characterization of anti–LAG-3 and anti–PD-1 combination treatment in patients with melanoma. Journal of Clinical Investigation. 133(6).
4.
Taimela, Simo, et al.. (2022). Time series analysis of the incidence of acute upper respiratory tract infections, COVID-19 and the use of antibiotics in Finland during the COVID-19 epidemic: a cohort study of 833 444 patients. BMJ Open. 12(1). e046490–e046490.
5.
Virtakoivu, Reetta, Jenna H. Rannikko, Miro Viitala, et al.. (2021). Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial. Clinical Cancer Research. 27(15). 4205–4220.
6.
Bono, Petri, Panu Jaakkola, Shishir Shetty, et al.. (2020). 1024MO A phase I/II MATINS trial: Part 1 pharmacokinetic, safety and efficacy results of Clever-1 blockade in advanced cancer. Annals of Oncology. 31. S706–S707.
7.
Sharma, Padmanee, Arlene O. Siefker‐Radtke, Filippo de Braud, et al.. (2020). 749P Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC): Extended follow-up from CheckMate 032. Annals of Oncology. 31. S582–S583.
8.
Österlund, Pia, Päivi Halonen, Tapio Salminen, et al.. (2020). SO-18 Single-arm multicentre phase II study of bevacizumab (B) combined with 9-weekly alternating CAPOX and CAPIRI as first-line treatment of patients with metastatic colorectal cancer (mCRC): Main results of the AXOAXI-trial. Annals of Oncology. 31. S223–S223.
9.
Sharma, Padmanee, Arlene O. Siefker‐Radtke, Filippo de Braud, et al.. (2019). Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. Journal of Clinical Oncology. 37(19). 1608–1616.
10.
Auclin, Édouard, Philippe Barthélémy, Petri Bono, et al.. (2019). Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma. European Journal of Cancer. 108. 33–40.
11.
Peltola, Katriina, Petri Bono, Robert H. Jones, et al.. (2018). ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer. European Urology Focus. 6(1). 63–70.
12.
Peltola, Katriina, et al.. (2017). Correlation of c-Met Expression and Outcome in Patients With Renal Cell Carcinoma Treated With Sunitinib. Clinical Genitourinary Cancer. 15(4). 487–494.
13.
Ott, Patrick A., Dung T. Le, Paolo A. Ascierto, et al.. (2017). Nivolumab (NIVO) in patients (pts) with advanced (adv) chemotherapy-refractory (CT-Rx) esophagogastric (EG) cancer according to microsatellite instability (MSI) status: checkmate 032. Annals of Oncology. 28. v229–v230.
14.
Joensuu, Heikki, Mikael Eriksson, Kirsten Sundby Hall, et al.. (2015). Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial. Journal of Clinical Oncology. 34(3). 244–250.
15.
Loi, Sherene, Stefan Michiels, Diether Lambrechts, et al.. (2013). Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer. JNCI Journal of the National Cancer Institute. 105(13). 960–967.
16.
Joensuu, Heikki, Pirkko‐Liisa Kellokumpu‐Lehtinen, Riikka Huovinen, et al.. (2013). Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica. 53(2). 186–194.
17.
Rivinoja, Antti, Johan Lundin, Maija Hyvönen, et al.. (2011). An Extensive Tumor Array Analysis Supports Tumor Suppressive Role for Nucleophosmin in Breast Cancer. American Journal Of Pathology. 179(2). 1004–1014.
18.
Joensuu, Heikki, Jeff Sperinde, M. Leinonen, et al.. (2011). Very high quantitative tumor HER2 content and outcome in early breast cancer. Annals of Oncology. 22(9). 2007–2013.
19.
Nevo, Jonna, Elina Mattila, Teijo Pellinen, et al.. (2009). Mammary-Derived Growth Inhibitor Alters Traffic of EGFR and Induces a Novel Form of Cetuximab Resistance. Clinical Cancer Research. 15(21). 6570–6581.
20.
Bono, Petri, Andreas Krause, Margaret von Mehren, et al.. (2004). Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib. Blood. 103(8). 2929–2935.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by E. Gabriela Chiorean Breakdown of academic impact, for papers by Robert R. McWilliams Breakdown of academic impact, for papers by Ferry A.L.M. Eskens Breakdown of academic impact, for papers by Helmut E. Gabbert Breakdown of academic impact, for papers by Catherine Delbaldo Breakdown of academic impact, for papers by Joseph P. Eder Breakdown of academic impact, for papers by Marisa Dolled‐Filhart Breakdown of academic impact, for papers by Napoleone Ferrara Breakdown of academic impact, for papers by Maurizio Martini Breakdown of academic impact, for papers by Laura D. Wood